xRead - September 2022

Wise et al.

Page 413

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study

Study Year LOE design Study groups Clinical endpoint Conclusion Spertini et al. 1589 2016 1b RDBPCT 1 Bet v 1-derived contiguous overlapping peptides 50 μ g; Combined rhinoconjunctivitis symptom and medication scores, QOL Improved symptom, medication, and QOL scores in both treatment groups vs placebo. Couroux et al. 1599 2015 1b RDBPCT 1 Cat-PAD 8 doses 3 nmol; 2 Cat-PAD 4 doses 6 nmol; 3 Control Rhinoconjunctivitis symptom scores 2 years after start of

Significant reduction in symptoms was observed in the 6 nmol dose group but not the other groups.

Patel et al. 1065 2013 1b DBPCT 1 Fel d 1-derived peptide 8 × 3 nmol 2 weeks apart; 2 Fel d 1-derived peptide 4 × 6 nmol 4 weeks apart; 3 8 × placebo Purohit et al. 1600 2008 1b DBPCT 1 Pre-seasonal Bet v 1 primer; 2 Pre-seasonal Bet v 1 fragments; 3 Placebo No significant difference in symptom and medication scores between the groups. Oldfield et al. 1601 2002 1b RCT 1 Fel d 1 peptide 90 μ g; 2 Placebo Total rhinoconjunctivitis score at 20 weeks and 52 weeks Durable treatment effect at 1 year with best regimen 4 × 6 nmol at 4 weeks apart. Primary: symptom medication scores; Secondary: skin and nasal sensitivities, immunoglobulins, adverse reactions

Increase in late respiratory reaction with treatment. Tolerance may

develop with continued treatment.

Improvement in pulmonary function. Increased incidence of late adverse reaction.

Dose response was observed at highest dose, resulting in the most significant decrease in lung and

nasal symptoms upon cat exposure.

Symptom-medication scores Subjects receiving the peptide fragment preparation had improved scores vs other groups.

treatment, symptom scores after challenge

Development of late respiratory reaction

Improvement in pulmonary function, adverse events

Nose, lung, and symptom scores during live cat exposure

2 750 μ g/dose SC Allervax Cat peptide; 3 Placebo

3 750 μ g Allervax CAT peptide; 4 Placebo

Norman et al. 1603 1996 1b RDBPCT 1 7.5 μ g Allervax CAT peptide;

Maguire et al. 1602 1999 1b RCT 1 75 μ g/dose SC Allervax Cat peptide;

2 75 μ g Allervax CAT peptide;

2 Bet v 1-derived contiguous overlapping peptides 100 μ g; 3 Placebo

1 Pre-seasonal ragweed;

2 Pre-seasonal ragweed peptide fragments; 3 Histamine placebo control

Litwin et al. 1604 1991 2b Placebo controlled trial

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.